The Regulator of G-protein Signaling 18 (RGS18) is a member of the RGS protein family, which functions as GTPase-activating proteins (GAPs) to negatively regulate G-protein-coupled receptor (GPCR) signaling by accelerating GTP hydrolysis on Gα subunits. RGS18 is predominantly expressed in platelets, megakaryocytes, and certain immune cells, where it modulates signaling pathways critical for platelet activation, hemostasis, and inflammatory responses. Its role in attenuating Gαq and Gαi/o signaling makes it a key regulator of thrombotic and immune processes.
RGS18-specific antibodies are essential tools for studying its expression, localization, and functional interactions. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in investigations of RGS18's physiological and pathological roles. Research has linked RGS18 dysregulation to bleeding disorders, thrombocytopenia, and cancer metastasis, highlighting its potential as a therapeutic target or biomarker.
The development and validation of high-affinity RGS18 antibodies are crucial for elucidating its mechanisms in platelet signaling cascades, immune cell regulation, and disease progression. Such reagents support translational studies aiming to modulate RGS18 activity in thrombosis, inflammation, or oncology-related pathways, underscoring its growing relevance in biomedical research.